Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab are established as standard treatment for neovascular age-related macular degeneration (nAMD). For statistical reasons, most clinical trials include 1 study eye per patient. Although ≤50% of patients with nAMD in 1 eye may develop fellow eye involvement within 5 years,1 few data are available on treatment outcomes in these second affected eyes. Herein, we report such outcomes in patients with bilateral disease from the collaborative Fight Retinal Blindness! (FRB!) Project,2 which has designed and established an efficient, web-based system to track outcomes of patients receiving treatment for nAMD in clinical practice.